Physician profile
Michelle Voet
NPI 1982688909
$439.62
in general payments reported to CMS, 2019-2025
12 companies · $113 in 2025
The $113 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2023: $20.95 · 2024: $194 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $328.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $124.99 | 2024 | |
| Corium, LLC | $74.58 | 2024-2025 | Azstarys |
| Pfizer INC. | $37.34 | 2024-2025 | |
| Adlon Therapeutics L.P. | $33.14 | 2019 | |
| Sanofi Pasteur INC. | $32.77 | 2019-2023 | |
| Tris Pharma INC | $29.58 | 2019-2025 | Dyanavel Xr |
| Sobi, INC | $21.65 | 2019 | |
| Cranial Technologies, INC | $19.34 | 2024 | Doc Band |
| Supernus Pharmaceuticals, INC. | $19.28 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $17.57 | 2019 | |
| Noven Therapeutics, LLC | $16.88 | 2025 | Xelstrym |
| Kaleo, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Voet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.